Your browser doesn't support javascript.
loading
A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia.
Jen, Wei-Ying; Jabbour, Elias; Short, Nicholas J; Issa, Ghayas C; Haddad, Fadi G; Jain, Nitin; Pemmaraju, Naveen; Daver, Naval G; Masarova, Lucia; Borthakur, Gautam; Chien, Kelly; Garris, Rebecca; Kantarjian, Hagop M.
Affiliation
  • Jen WY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Haddad FG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Masarova L; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Chien K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Garris R; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Am J Hematol ; 2024 Aug 28.
Article in En | MEDLINE | ID: mdl-39194286
ABSTRACT
Twenty adults with newly diagnosed (ND) or relapsed/refractory (RR) Ph-positive acute lymphoblastic leukemia (ALL), or chronic myeloid leukemia in lymphoid blast phase (CML-LBP), were treated with mini-hyperCVD, ponatinib, and blinatumomab. Complete molecular response was achieved in 78% of ND patients, while CR/CRi was achieved in 100% of RR and CML-LBP. The 3-year overall survival rate was 76% (95% CI, 47%-90%).
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Am J Hematol Year: 2024 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Am J Hematol Year: 2024 Document type: Article Affiliation country: United States Country of publication: United States